web 2086 has been researched along with ym 264 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horie, M; Mase, T; Nagaoka, H; Sakurai, Y; Tomioka, K; Yamada, T | 1 |
| Bird, IN; Daniels, RH; Elmore, MA; Finnen, MJ; Hill, ME | 1 |
2 other study(ies) available for web 2086 and ym 264
| Article | Year |
|---|---|
Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat.
Topics: Animals; Azepines; Disease Models, Animal; Glomerulonephritis, Membranous; Hypercholesterolemia; Male; Metabolic Clearance Rate; Methylprednisolone; Piperazines; Platelet Activating Factor; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidines; Ticlopidine; Triazoles | 1991 |
Endothelial cell-associated platelet-activating factor primes neutrophils for enhanced superoxide production and arachidonic acid release during adhesion to but not transmigration across IL-1 beta-treated endothelial monolayers.
Topics: Arachidonic Acid; Azepines; Cell Adhesion; Cell Movement; Cell Polarity; Endothelium, Vascular; Humans; In Vitro Techniques; Interleukin-1; Neutrophil Activation; Neutrophils; Piperazines; Platelet Activating Factor; Superoxides; Thiazoles; Thiazolidines; Triazoles | 1994 |